Franklin Resources
SYRE icon

Franklin Resources’s Spyre Therapeutics SYRE Stock Holding History

Franklin Resources’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131M Buy
1,472,943
+590,110
+67% +$43.1M 0.03% 397
2026
Q1 		$44.5M Sell
882,833
-226,441
-20% -$8.54M 0.01% 683
2025
Q4 		$36.3M Buy
1,109,274
+313,999
+39% +$8.2M 0.01% 743
2025
Q3 		$13.3M Hold
795,275
– – ﹤0.01% 1080
2025
Q2 		$11.9M Buy
795,275
+34,647
+5% +$513K ﹤0.01% 1076
2025
Q1 		$12.3M Sell
760,628
-14
-0% -$291 ﹤0.01% 1047
2024
Q4 		$17.7M Sell
760,642
-24
-0% -$704 ﹤0.01% 948
2024
Q3 		$23.3M Buy
760,666
+18,762
+3% +$522K 0.01% 851
2024
Q2 		$17.4M Hold
741,904
– – 0.01% 901
2024
Q1 		$28.1M Buy
741,904
+54,814
+8% +$1.59M 0.01% 755
2023
Q4 		$14.8M Buy
+687,090
New +$9.47M 0.01% 834
2023
Q3 		– Sell
-1,255
Closed -$14.1K – 2779
2023
Q2 		$14.1K Hold
1,255
– – ﹤0.01% 2683
2023
Q1 		$9.1K Hold
1,255
– – ﹤0.01% 2284
2022
Q4 		$14.1K Hold
1,255
– – ﹤0.01% 2292
2022
Q3 		$16K Hold
1,255
– – ﹤0.01% 2268
2022
Q2 		$16K Sell
1,255
-597
-32% -$20.9K ﹤0.01% 2325
2022
Q1 		$106K Buy
+1,852
New +$156K ﹤0.01% 2287

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Franklin Resources's SYRE Position: Q2 2026 in Review

Franklin Resources increased its Spyre Therapeutics (SYRE) stake by 67% in Q2 2026, buying an estimated $43.1M and bringing the position to 1,472,943 shares worth $131M. The position accounts for 0.03% of the portfolio, ranked #397.

Franklin Resources first reported a position in SYRE in Q1 2022 and has held it in 17 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Franklin Resources held 1,472,943 shares of Spyre Therapeutics worth $131M as of Q2 2026.
  • Franklin Resources bought 590,110 Spyre Therapeutics shares in Q2 2026, an estimated $43.1M.
  • Spyre Therapeutics made up 0.03% of Franklin Resources's portfolio in Q2 2026, its #397 holding.
  • Franklin Resources first reported a position in Spyre Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.